CVS Health Q1 Earnings to Benefit From Favorable Medical Loss Ratio, UBS Says

MT Newswires Live

Apr 30, 2025

CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.

The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.

The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.

UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.

The firm has a neutral rating on CVS stock with a $67 price target.

Price: 65.31, Change: +0.38, Percent Change: +0.59

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531798751"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531798751\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531798751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 02:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531798751","market":"nz","top_or_hot":-1,"title":"CVS Health Q1 Earnings to Benefit From Favorable Medical Loss Ratio, UBS Says","media":"MT Newswires Live","content":"<html><body><p> CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.</p><p>The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.</p><p>The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.</p><p>UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.</p><p>The firm has a neutral rating on CVS stock with a $67 price target.</p><p>Price: 65.31, Change: +0.38, Percent Change: +0.59</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS Health Q1 Earnings to Benefit From Favorable Medical Loss Ratio, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS Health Q1 Earnings to Benefit From Favorable Medical Loss Ratio, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-30 02:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.</p><p>The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.</p><p>The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.</p><p>UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.</p><p>The firm has a neutral rating on CVS stock with a $67 price target.</p><p>Price: 65.31, Change: +0.38, Percent Change: +0.59</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西维斯健康","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2531798751","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531798751","pubTimestamp":1745953167,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CVS Health  Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.The firm has a neutral rating on CVS stock with a $67 price target.Price: 65.31, Change: +0.38, Percent Change: +0.59","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"瑞银表示，CVS Health第一季度盈利将受益于有利的医疗损失率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.The firm has a neutral rating on CVS stock with a $67 price target.Price: 65.31, Change: +0.38, Percent Change: +0.59","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}